AcelRx changing its name to Talphera

AcelRx announced the rebranding of the company, with a name change to Talphera. The rebrand decision was made to reflect the company’s strategy of developing and commercializing products to support advancing care to optimize outcomes in medically supervised settings, moving beyond the original focus on acute pain. Talphera will commence trading on the Nasdaq Global Market under the ticker symbol “TLPH” effective January 10. The company’s lead nafamostat product candidate, Niyad, is expected to have a Premarket Approval submission to the FDA in the second half of 2024. The name Talphera was derived from “Talisman”. The company’s new mission at Talphera is to support healthcare providers by developing and commercializing products in medically supervised settings that deliver advances in care to patients. Talphera expects to initiate the registrational study of Niyad shortly. The study has already received central Institutional Review Board approval. The first patient is expected to be enrolled for the NEPHRO study in Q1.